StockData

Orchestra BioMed Holdings, Inc. (OBIO) stock

OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$7.00−0.46 (-6.17%)

Close on Nov 19, 2026Market cap $420.74MP/E –Yield –

Orchestra BioMed free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Orchestra BioMed's free cash flow for the twelve months ending Jun 30, 2026 was -$59.10M. For fiscal 2025 it was -$49.45M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$49.45M–
FY2024Dec 31, 2024-$50.85M–
FY2023Dec 31, 2023-$46.21M–
FY2022Dec 31, 2022-$29.88M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.59M–
Q1 FY2026Mar 31, 2026-$22.35M–
Q4 FY2025Dec 31, 2025-$2.30M–
Q3 FY2025Sep 30, 2025-$14.86M–
Q2 FY2025Jun 30, 2025-$15.56M–
Q1 FY2025Mar 31, 2025-$16.73M–
Q4 FY2024Dec 31, 2024-$13.64M–
Q3 FY2024Sep 30, 2024-$13.77M–
Q2 FY2024Jun 30, 2024-$10.31M–
Q1 FY2024Mar 31, 2024-$13.12M–
Q4 FY2023Dec 31, 2023-$10.97M–
Q3 FY2023Sep 30, 2023-$10.30M–
Q2 FY2023Jun 30, 2023-$10.52M–
Q1 FY2023Mar 31, 2023-$14.42M–
Q4 FY2022Dec 31, 2022-$8.80M–
Q3 FY2022Sep 30, 2022-$7.48M–
Q2 FY2022Jun 30, 2022-$8.23M–
Q1 FY2022Mar 31, 2022-$5.37M–

More Orchestra BioMed figures

See a number that looks wrong?